A phase II trial of oral idarubicin plus dibromodulcitol in advanced breast cancer.
Smith
D B
DB
Cancer Research Campaign, Department of Medical Oncology, Christie Hospital, Manchester, U.K.
Howell
A
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D008875:Middle Aged; D008936:Mitolactol / Q000008:administration & dosage; D009503:Neutropenia / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced
D008936:Mitolactol; D015255:Idarubicin